Evidence map›Paper›PMID 32743788›Full record

ArticleJournal of the Egyptian National Cancer Institute2020

Initial absolute monocyte count as an immune biomarker for clinical response in acute myeloid leukemia with monocytic differentiation.

Ahmed Embaby, Ayman Fathy, Mohammad Al-Akkad, Ahmad Baraka, Taiseer Ibrahim, Nahla Zidan, Mohamed Refaat, Haitham Elsheikh

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Egyptian National Cancer Institute, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Anorectal Pathologies in the Course of Acute Leukaemias; Predictive Parameters.Mediterranean journal of hematology and infectious diseases · 2024
    Article
  3. Article
  4. Monocytic Myeloid-Derived Suppressor Cells But Not Monocytes Predict Poor Prognosis of Acute Myeloid LeukemiaTurkish journal of haematology : official journal of Turkish Society of Haematology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ahmed EmbabyClinical Hematology Unit, Internal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Al-Sharika, 44519, Egypt. Dr.embaby@yahoo.com.ORCID https://orcid.org/0000-0002-9078-0463
Ayman FathyClinical Hematology Unit, Internal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Al-Sharika, 44519, Egypt.
Mohammad Al-AkkadClinical Hematology Unit, Internal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Al-Sharika, 44519, Egypt.
Ahmad BarakaClinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Taiseer IbrahimPathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Nahla ZidanClinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Mohamed RefaatClinical Oncology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Haitham ElsheikhClinical Hematology Unit, Internal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Al-Sharika, 44519, Egypt.
Zagazig University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAbsolute monocyte count (AMC) correlates with survival outcomes in various hematologic malignancies. However, its role in myeloid malignancies including AML needs to be highlighted. So, this prospective cohort study aimed to assess the effect of AMC on the treatment outcome and survival in a 56 adult de novo AML patients with monocytic differentiation, admitted to the Clinical Hematology Unit, Internal Medicine Department, in a tertiary referral hospital in Egypt, from July 2016 to June 2019.

resultsThe initial AMC was measured either by manual differential or the hematology automatic analyzer Sysmex XN-2000 and patients were classified by using receiver operating characteristic curve into two groups monocytopenic (≤ 4 × 10

conclusionInitial AMC was found to be an independent prognostic immune biomarker for treatment response in AML patients with monocytic differentiation. However, it did not appear as an independent predictor of survival in a multivariate analysis.

Indexed as

Leukemia, Myeloid, AcuteMonocytesAdultBiomarkersEgyptHumansPrognosisProspective StudiesRetrospective StudiesBiomarkersAbsolute monocyte countAcute myeloid leukemiaImmune biomarkerMonocytic differentiationResponse

Identifiers

PMID32743788
PMCPMC13317110
OpenAlexW3046367385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.